1255099-06-9
1255099-06-9
Chemical Structure
SKLB-163
- CAS No.: 1255099-06-9
- Formula:C18H16ClN3O2S2
- Molecular Weight:405.92
IUPAC Name: N-benzyl-2-((6-(2-chloroacetamido)benzo[d]thiazol-2-yl)thio)acetamide
InChIKey: BYIJUMAHXVZITK-UHFFFAOYSA-N
SMILES: O=C(CSC1=NC2=CC=C(C=C2S1)NC(CCl)=O)NCC3=CC=CC=C3
Biological Activity: SKLB-163 is an orally active inhibitor for Rho GDP-dissociation (RhoGDI). SKLB-163 inhibits highly expressed RhoGDI tumor cell proliferation and migration, and increases radiosensitivity of tumor cells. SKLB-163 induces cancer cell Apoptosis[1][2].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
SKLB-163 | SKLB-163 is an orally active inhibitor for Rho GDP-dissociation (RhoGDI). SKLB-163 inhibits highly expressed RhoGDI tumor cell proliferation and migration, and increases radiosensitivity of tumor cells. SKLB-163 induces cancer cell Apoptosis. | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
References
- [1]. He J, et al. Antitumor and radiosensitizing effects of SKLB-163, a novel benzothiazole-2-thiol derivative, on nasopharyngeal carcinoma by affecting the RhoGDI/JNK-1 signaling pathway. Radiother Oncol. 2018 Oct;129(1):30-37. [Content Brief]
- [2]. Peng X,et al. SKLB-163, a new benzothiazole-2-thiol derivative, exhibits potent anticancer activity by affecting RhoGDI/JNK-1 signaling pathway. Cell Death Dis. 2014 Mar 27;5(3):e1143. [Content Brief]
